The European Medicines Agency (EMA) has approved the drug donanemab, which will be marketed under the name Kisunla, for the treatment of early-stage Alzheimer's disease. The decision was made after a ...
New Drug for Early-Stage Alzheimer's Disease Approved in the European Union